Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients

Status: Recruiting
Location: See location...
Intervention Type: Genetic
Study Type: Observational
SUMMARY

Donor-derived cell-free DNA (dd-cfDNA) has been proposed as a potential diagnostic tool to monitor the rejection status of the kidney transplant. It has been suggested that dd-cfDNA is increasing in the blood of kidney transplant patient presenting a graft rejection. In this project, investigators proposed a different approach to predict and characterize kidney transplant rejection/dysfunction based on the quantification of epigenetic signatures present on the donor-cell-free DNA. In 2018, Moss et al. develops a deconvolution model capable of identifying the tissue origin of circulating DNA by taking advantage of its epigenetic properties. The study confirmed that the cell-free DNA circulating in healthy subjects comes mainly from blood cells and endothelial cells, but not from kidney cells. In this study, researchers investigate the evolution of blood renal-specific cell-free DNA amount in patient with chronic kidney disease before and after the transplantation surgery by testing a set of renal-specific epigenetic markers. The purpose of this study is to identify the biological noise of native kidney on renal-specific cell-free DNA and to compare it with signal coming from transplanted kidney.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥ 18 years old

• With end-stage renal failure

• Summoned for a kidney transplant at Pitié Salpêtrière Hospital

• Having been informed of the study and not objecting to the study having given free and informed written consent for the genetic analysis

• Benefiting from a social security scheme (excluding AME)

Locations
Other Locations
France
Pitié-Salpétriêre Hospital
RECRUITING
Paris
Contact Information
Primary
Sarah Dr DROUIN, MD-PhD
sarah.drouin@aphp.fr
+33 1 42 17 71 73
Backup
Geoffroy Dr POULET, PhD
Geoffroy.poulet@cgenetix.com
+33 6 67 77 23 94
Time Frame
Start Date: 2024-09-02
Estimated Completion Date: 2026-07-09
Participants
Target number of participants: 30
Related Therapeutic Areas
Sponsors
Leads: Assistance Publique - Hôpitaux de Paris

This content was sourced from clinicaltrials.gov